SEC Form 4 · accession 0001136261-19-000011
SEELOS THERAPEUTICS, INC. · SEEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raj Mehra
Officer — See Remarks · Director · 10% Owner
Period of report
Jan 24, 2019
Accepted (ET)
Jan 28, 2019 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001017491
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 24, 2019 | A | 3,081,546 | — | A | 3,081,546 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares of common stock of the corporation formerly known as Seelos Therapeutics, Inc. ("Seelos") were converted into shares of common stock of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of July 30, 2018, by and among the Issuer, Arch Merger Sub, Inc. and Seelos, as amended (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Seelos common stock was exchanged for 0.7704 shares of the Issuer's common stock. Immediately following the merger, the Issuer changed its name to Seelos Therapeutics, Inc. All share numbers reflect the one-for-thirty reverse stock split effected by the Issuer immediately prior to the completion of the merger.
Remarks
President, Chief Executive Officer, Chairman of the Board of Directors and Interim Chief Financial Officer